As of Nov 19, 2026, 1 of 1 active firms rate VYGR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VYGR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.52 – $-0.33 · 4 analysts · -9% YoY
Next period, 4 analysts expect Voyager Therapeutics Inc to earn $-0.43 a share (range $-0.52 – $-0.33), versus $-0.47 a year earlier. Full-year consensus is $-1.69, growing to $-1.31 the year after.
REVENUE · NEXT QUARTER
$5.6M
Range $2.5M – $11.8M · 4 analysts · +114% YoY
Revenue is expected to reach $5.6M (range $2.5M – $11.8M), +114.5% year-over-year. Full-year consensus is $15.5M, rising to $45.3M next year.
Top analysts covering Voyager Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VYGR.
#1
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$22.00+1213.4% to target
Overall win rate
39%
+ Follow
#2
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton VYGR
Overall win rate
35%
+ Follow
#3
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$25.00+1392.5% to target
Overall win rate
36%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$11.00+556.7% to target
Overall win rate
41%
+ Follow
#5
Sumant Kulkarni
Canaccord Genuity · Rank #419
Buy
$12.00+616.4% to target
Overall win rate
39%
+ Follow
VYGR stock forecast FAQ
What is VYGR's average 12-month price target?+
The 1 active firms with a live target average $25.00 for Voyager Therapeutics Inc over the next 12 months, ranging from a $25.00 high to a $25.00 low, as of Nov 19, 2026.
Is VYGR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover VYGR?+
1 active firms have a recognized rating on Voyager Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VYGR?+
Among analysts who currently cover VYGR, Debjit Chattopadhyay of Guggenheim has the strongest overall Quantellect track record (Rank #248). Their current call is Buy with a $22.00 target.
What is Voyager Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.52 – $-0.33) across 4 analysts. Full-year EPS is projected at $-1.69, rising to $-1.31 the following year.
How much revenue is Voyager Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.6M (range $2.5M – $11.8M). Full-year revenue is projected at $15.5M, growing to $45.3M next year.
Have analysts been upgrading or downgrading VYGR lately?+
As of Nov 19, 2026, 1 of 1 active firms rate VYGR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VYGR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.